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The orexins (ORX-A/ORX-B) are neuroactive peptides known to have roles in feeding and sleep. Evidence of dense, excitatory projections
of ORX-A neurons to the noradrenergic pontine nucleus, the locus ceruleus (LC), suggests ORX-A also participates in attention and
memory. Activation of LC neurons by glutamate produces a -adrenergic receptor-mediated long-term potentiation (LTP) of the per-
forant path-evoked potential in the dentate gyrus, a target structure of the LC that has been implicated in memory. We asked whether
ORX-A also activates norepinephrine (NE)-induced LTP by initiating NE release in the hippocampus. Here, we show that ORX-A infusion
(0.25–25 fmol) into the LC produces a robust,-adrenergic receptor-dependent, long-lasting potentiation of the perforant path-evoked
dentate gyrus population spike in the anesthetized rat. Pharmacological inactivation of the LC with an 2-adrenergic receptor agonist,
before ORX-A infusion, prevents this potentiation. Analysis of NE concentrations in the hippocampus after ORX-A infusion into the LC
reveals a transient, but robust, increase in NE release. Thus, this study demonstrates that the dense orexinergic projection to the LC
promotes the induction of NE-LTP in the dentate gyrus. ORX-A modulation of LC activity may provide important support for the
cognitive processes of attention and memory.
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Introduction
Orexin (ORX) was implicated initially in feeding and sleep (de
Lecea et al., 1998; Sakurai et al., 1998). However, ORX axons
project widely in the brain and spinal cord (Cutler et al., 1999;
Date et al., 1999; Nambu et al., 1999), suggesting ORX modulates
multiple brain and behavioral systems. ORX neurons originate in
the lateral hypothalamus, a region implicated in intracranial self-
stimulation (Milner, 1991) and in facilitating learning and mem-
ory (Destrade and Jaffard, 1978; Huston and Mueller, 1978; Cou-
lombe and White, 1980, 1982; Aldavert-Vera et al., 1996;
Redolar-Ripoll, 2002). Recent studies support a facilitating role
for ORX in tasks like those enhanced by lateral hypothalamic
stimulation (Jaeger et al., 2002; Telegdy and Adamik, 2002). We
propose one mechanism for ORX (and lateral hypothalamic) in-
volvement in learning and memory is the dense orexinergic in-
nervation of the locus ceruleus (LC) (Cutler et al., 1999; Date et
al., 1999; Nambu et al., 1999), which has a high density of mRNA
for the ORX-A receptor (Trivedi et al., 1998; Hervieu et al., 2001;
Marcus et al., 2001).
The LC is the primary source of forebrain norepinephrine
(NE) and is known to be involved in attention and memory (Ber-
ridge and Waterhouse, 2003). ORX neurons make asymmetrical
connections with tyrosine hydroxylase-positive neurons in the
LC, suggesting ORX provides excitatory input to noradrenergic
neurons (Horvath et al., 1999). Application of ORX in vitro or in
vivo increases LC activity (Hagan et al., 1999; Horvath et al., 1999;
Bourgin et al., 2000; van den Pol, 2002) and produces a
tetrodotoxin-resistant depolarization, indicating ORX directly
activates LC neurons (Ivanov and Aston-Jones, 2000).
One target of LC projections is the hippocampus, a structure
implicated in memory. The hippocampus has only modest ORX
input (Cutler et al., 1999; Nambu et al., 1999) and ORX receptor
density (Trivedi et al., 1998) but significant noradrenergic inner-
vation, particularly in the dentate gyrus (Loy et al., 1980). NE
produces a long-lasting potentiation of the glutamatergic per-
forant path input to the dentate gyrus (Neuman and Harley,
1983). This NE-induced long-term potentiation (NE-LTP) oc-
curs without tetanization. Glutamatergic activation of the LC
induces LC firing (Harley and Sara, 1992) and produces a long-
lasting, -adrenergic receptor-dependent potentiation of the
dentate gyrus population spike (Harley and Milway, 1986; Harley
and Evans, 1988). However, duration of potentiation in vivo with
NE application or glutamatergic LC activation is variable, and
only 50% of experiments demonstrate potentiation exceeding
30 min. In vitro, -adrenergic receptor-dependent NE-LTP is
consistently long lasting, accompanied by increases in cAMP
(Stanton and Sarvey, 1985a) and dependent on protein synthesis
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(Stanton and Sarvey, 1985b), common characteristics of memory
mechanisms.
Presently, there is little evidence linking the robust ORX in-
nervation of the LC to a physiological action of the LC in a target
structure. The present study demonstrates that ORX-A infused in
the LC produces robust, transient NE release in the hippocampus
and consistent NE-LTP in the dentate gyrus. This long-lasting
potentiation depends on -adrenergic receptors and is sustained
for hours after the transient NE elevation in the hippocampus.
Materials and Methods
Electrophysiologial experiments
Subjects and surgical procedures. Subjects were male Sprague Dawley rats,
250 – 400 gm (Memorial University of Newfoundland), receiving water
and regular rat chow ad libitum and housed under climate-controlled
conditions with a 12 hr light/dark cycle (lights on at 8:00 A.M.). All
animal procedures were reviewed by the Institutional Animal Care Com-
mittee and were in conformity with the guidelines set out by the Cana-
dian Council on Animal Care.
Rats were anesthetized with urethane (1.5 gm/kg, i.p.) and placed in a
stereotaxic instrument in the skull flat position. Trephine holes were
drilled for electrodes and cannula placement. A 22 gauge guide cannula
(Plastics One, Roanoke, VA), angled 20° from the vertical, was implanted
2.3–2.5 mm above the LC [12.5–12.6 mm posterior and 1.3 mm lateral
from the midline] and secured with dental acrylic to a small jeweler’s
screw. A concentric bipolar stimulating electrode (NE-100; Kopf Instru-
ments, Tujunga, CA) was directed at the perforant path (7.2 mm poste-
rior and 4.1 mm lateral to bregma and 3.0 mm ventral from brain
surface). An adjustable dual recording assembly allowing independent
manipulation of two glass micropipettes, one filled with saline and the
other with the -adrenergic antagonist propranolol (PROP; 100 mM;
Sigma, St. Louis, MO), was aimed at the granule cell layer of the dentate
gyrus (3.5 mm anteroposterior and 2.0 mm lateral from bregma and
2.5–2.8 mm from brain surface). The tips of the pipettes were separated
by500 –750 m.
Stimulation and recording. The perforant path was stimulated at 0.5 Hz
(0.2 msec monophasic pulse). The evoked responses from the granule
cell layer were filtered (1 Hz to 3 kHz) and digitized at 10 kHz. The
recording pipettes (3–5 M) were maneuvered to provide maximal pos-
itive going waveforms. Initially, an input– output current intensity series
(I/O curve) was determined (50 –1000 A, using 50 A increments),
sampling three evoked potentials at each current level (interstimulus
interval, 10 sec). The current intensity used for baseline measurements
was the current producing 50% of the maximal population spike.
Waveforms were collected using DataWave software and analyzed off-
line. Evoked responses were sampled every 30 sec for a minimum of 1 hr
before drug infusion.
Pharmacology. ORX-A (California Peptide, Napa, CA) was made up in
sterile saline (100 pM, 1 nM, 10 nM, 100 nM) and kept frozen until used. An
infusion cannula (28 gauge; Plastics One) was attached to a 0.5l micro-
syringe by autoanalyzer tubing (Fisher Scientific, Pittsburgh, PA) and
gently lowered into the LC. ORX-A or saline (200 –250 nl) was infused
into the LC over a period of 30 – 60 sec, and the infusion cannula was left
in place for 3 min after the infusion. DL-PROP (100 mM; Sigma), used in
the second recording pipette, was mixed fresh in sterile saline. DL-PROP
has been shown to be effective in blocking dentate gyrus noradrenergic-
induced potentiation in vitro (Lacaille and Harley, 1985; Stanton and
Sarvey, 1985b; Dahl and Sarvey, 1989). Of importance for the present
study, DL-PROP has blocked the effects of LC activation in potentiating
the dentate gyrus-evoked potential in vivo. We previously used DL-PROP
(Harley and Evans, 1988) and timolol (Harley and Evans, 1988; Munro et
al., 2001) in micropipettes to attenuate noradrenergic effects in the den-
tate gyrus, but the report that PROP, not timolol, blocks lateral perforant
path potentiation in vitro (Bramham et al., 1997) led us to select PROP
here. To directly block LC activation, clonidine (CLON; 3.75 mM; Sigma)
was mixed in saline, and 200 nl was infused into the LC 5 min before
ORX-A (1 nM). A similar concentration of CLON has been shown pre-
viously to silence LC neurons (Berridge et al., 1993).
Microdialysis experiments
Subjects were male Wistar rats (260 –300 gm) obtained from Bantin and
Kingman (Hull, UK). Food and water was available ad libitum. All animal
procedures were performed in accordance with the requirements of the
United Kingdom Animals (Scientific Procedures) Act, 1986.
Rats were anesthetized with urethane (1.5 gm/kg, i.p.) and placed in a
stereotaxic instrument in the skull flat position. Holes were drilled for
placement of a microdialysis probe (5.3 mm posterior and 5 mm lateral
to bregma) directed at the hippocampus, and a 22 gauge guide cannula
(12.4 mm posterior and 1.2 mm lateral to bregma with a 20° angle from
vertical) was directed at the LC. The probe was placed 6.5 mm below
brain surface, and the guide cannula was lowered to 5.5 mm below brain
surface. A 28 gauge infusion cannula extended an additional 1 mm when
inserted. The guide cannula was lowered in 0.5 mm steps if no effect of
ORX-A infusion on NE release was observed. ORX-A (a gift from Dr.
M. S. Harbuz, University of Bristol, Bristol, UK) was mixed in saline and
kept frozen until required.
NE diasylate in the hippocampus was obtained using a concentric
dialysis probe constructed as described by Harley et al. (1996), but using
a 4 mm exposed membrane. The larger probe provided a more stable
sample of NE levels. To reach a greater area of hippocampal tissue, it was
placed 1.8 mm more posterior than the recording site. The assumption
was made that relative changes in NE release will reflect the influence of
LC activity throughout the hippocampus. All subregions of the hip-
pocampus, including the dentate gyrus, were sampled at the probe site.
The microdialysis probe was perfused continually (1.19 l/min) with
artificial cerebrospinal fluid (in mM: 147 NaCl, 3 KCl, 1.3 CaCl2, and 1
MgCl2). Samples of 20l were collected every 20 min until three consec-
utive baseline samples were stable. After ORX-A infusion into the LC,
sampling continued until NE returned to baseline. Analysis of NE was
performed by means of HPLC with electrochemical detection (Harley et
al., 1996). In brief, the mobile phase was prepared using a stock mixture
of 24 mM sodium acetate, 15 mM citric acid, and 2.3 mM octane–sulfonic
acid in deionized water, to which methanol (13% v/v) was added. The pH
was adjusted to 5.0 with 10 mM NaOH before filtering and degassing. The
mobile phase was then pumped through the system at a rate of 1.0 ml/
min (3 m ODS; 12.5 cm length, 4.6 mm inner diameter; Hichrom,
Theale, Berkshire, UK) while being maintained at a temperature of
32.5°C. Electrochemical detection was performed via an Antec Leyden
Intro detector with the flow cell set at a potential of700 mV and output
to a chart recorder. NE standards were run before each experiment.
Histology and statistical analysis
On the conclusion of all experiments, a final infusion of 200 –250 nl of
1% methylene blue (electrophysiology) or polygraph ink mixed 50%
with 0.25 M glutamate (microdialysis) was infused into the LC to mark
the infusion site. Rats were decapitated, and the brains were removed
quickly and frozen. Saggital sections (30 m) were taken to verify LC
cannula placement.
Population spike amplitude and EPSP slope were measured as detailed
in the inset to Figure 1. Briefly, the population spike amplitude was
measured as the difference between the peak and valley of the downward
deflecting spike (c). The EPSP slope was measured as: voltage (b-a)/time
(a-b). There were no significant differences in baseline EPSP slope or
population spike amplitude between the saline and PROP pipettes before
commencement of the experiments.
The effects of ORX-A infusion in the LC were determined by averaging
the last 15 min of the 3 hr recording period after ORX infusion, and
responses were compared with the average of the 60 min baseline period.
Hippocampal NE levels measured by microdialysis were also compared
with baseline data. Repeated-measures ANOVAs were used on raw data,




Cannula placements for positive ORX-A effects were within 300
m of the LC, consistent with the dendritic arborization of this
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region (Aston-Jones et al., 1995). In the electrophysiological ex-
periments, placements (n 5) that were dorsoposterior to the LC
by 450 –700m were negative. In the microdialysis experiments,
negative ORX-A infusions were seen posterior (500 –1000 m;
n 3), dorsal (500 –1000 m; n 2) and ventral (400 m; n
2) to the LC. This pattern of placement results suggests ORX-A
infusions must be targeted relatively close to the nucleus to be
effective.
ORX-A infusion in the LC potentiates
perforant path-evoked population spike
amplitude through a-adrenergic
receptor mechanism
Analysis (ANOVA; group  infusion) of
the perforant path– dentate gyrus-evoked
population spike 3 hr after ORX-A infu-
sion into the LC showed a significant in-
teraction (F(4,25) 2.87; p 0.04; on raw
data). Post hoc analysis revealed that
ORX-A infusion into the LC produced an
increase of the population spike amplitude
at three concentrations of ORX-A (1 nM,
p 0.002; 10 nM, p 0.007; 100 nM, p
0.0004) (Fig. 1). Potentiation was not ob-
served with vehicle infusions (Fig. 1A,B,D)
or with 100 pM infusions (Fig. 1D). Potenti-
ation appeared more rapidly for the 1 nM
infusion than the 10 or 100 nM infusions,
which were similar (Fig. 1, compare A, C)
(time  concentration; F(1,8)  3.03; p 
0.007; post hoc effect at 1 hr time point).
For the three effective ORX-A concen-
trations, a two-way repeated-measures
ANOVA (concentration  pipette) was
performed to assess whether the -adre-
nergic antagonist PROP or the ORX con-
centration affected the final level of poten-
tiation. There was no differential effect of
concentration on the final potentiation
(mean potentiation at 3 hr, 155%). How-
ever, at the PROP pipette potentiation was
significantly reduced (F(1,12) 23.19; p
0.0004; mean final potentiation, 124%)
(Fig. 2A). There was no long-term effect of
ORX-A on EPSP slope at any concentra-
tion (Fig. 2B). ORX-A infusion did com-
monly elicit a modest, transient increase in
EPSP slope at infusion that returned to
baseline levels.
To address the specificity of LC activa-
tion, we infused CLON, an 2-adren-
ceptor agonist, into the LC to inhibit firing
5 min before an infusion of 1 nM ORX-A
(Fig. 3). Infusion of CLON before ORX-A
prevented the facilitation of the popula-
tion spike (CLON plus 1 nM ORX-A,
103%; final increase with 1 nM ORX-A,
156%), confirming the critical role of LC
activation in producing the potentiation
observed with ORX-A.
ORX-A infusion in the LC transiently
enhances NE release in
the hippocampus
Although application of the ORXs onto LC neurons by either
bath application (Hagan et al., 1999; van den Pol et al., 2002) or
by infusion into the LC in vivo (Bourgin et al., 2000; Kiyash-
chenko et al., 2001) can increase the firing rate of LC neurons, the
enduring change in response to the perforant path stimulus led us
to ask whether ORX-A infused into the LC was also producing an
enduring change in NE levels in the hippocampus. To assess this,
we sampled NE levels in the hippocampus using microdialysis
Figure 1. ORX-A infusion in the LC enhanced population spike amplitude at concentrations of 1 nM or higher. A, inset, Evoked
potential parameters measured were EPSP slope (b a/time) and population spike amplitude (c). Sample waveforms from one
rat at baseline (solid line) and at 180 min after 1 nM ORX-A (broken line). Calibration: 4 mV, 2 msec. A, Population spike amplitude
with vehicle (n 10) and 1 nM ORX-A (n 6) infusion in the LC. B, An experiment with saline infusion in the LC, followed 75 min
later by 1 nM ORX-A infusion. V, Vehicle. C, Population spike amplitude with 100 nM ORX-A infusion in the LC (n5). D, Population
spike amplitude for vehicle and the four concentrations of ORX-A 180 min after infusion in the LC. The data shown in A–C are 3 min
means SEM. The data in D illustrate 15 min averages (165–180 min after LC infusion) SEM. ##p0.01.
Figure 2. -Adrenergic receptor blockade in the dentate gyrus attenuated ORX-A potentiation effects. The EPSP slope was
unaffected. A, inset, Baseline waveforms from saline and PROP pipettes for one experiment. Calibration: 4 mV, 2 msec. Population
spike amplitude ( A) and EPSP slope ( B) patterns summed over the three effective concentrations of ORX-A (1–100 nM) for both the
saline and PROP pipettes are shown. PROP reduced the ORX-A effect on the population spike (F(1,12)  23.2; p 0.0004),
implicating activation of-adrenergic receptors in the dentate gyrus as mediators of the potentiation.
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before and after effective ORX-A (100 nM, 10 nM, 1 nM) infusion
into the LC. A repeated-measures ANOVA (concentration 
sample) was performed on the three baseline levels of hippocam-
pal NE to assess differences between groups (100 nM, 10 nM, 1 nM)
and across samples (3.0 to1.0). No differences were found in
basal levels of NE among the groups or among the three succes-
sive baseline NE responses, and, as expected, no interactions be-
tween concentrations and baseline samples were found. The
mean NE baselines across the three groups of ORX-A (100 nM, 10
nM, 1 nM) concentrations were 13.30, 13.88, and 13.24 fmol/20
l, respectively.
A second repeated-measures ANOVA (concentration sam-
ple) was performed comparing the mean of the baseline samples
to the three samples after ORX-A infusion into the LC (samples
1.0 –3.0). There were no differential effects because of the con-
centration of ORX-A infused, but there was a significant effect of
sample (F(3,30)  16.55; p  0.0001). Post hoc comparisons re-
vealed that the first NE sample for the 20 min after the infusion of
ORX-A into the LC was significantly increased above baseline for
each of the three concentrations of ORX-A (Fig. 4A–C). The
mean increase in the first sample averaged over the three effective
concentrations of ORX-A was 188% of baseline. Samples of NE in
the hippocampus taken in the subsequent 20 min periods did not
differ from baseline NE levels for any concentration of ORX-A, in-
dicating a transient release of NE after ORX-A activation of the LC.
To compare ORX-A with glutamate effects on NE release, and
to probe site effectiveness, glutamate infusions were performed at
the conclusion of 10 experiments. In each case, glutamate in-
creased NE release. In seven experiments, microdialysis measure-
ments were continued for an additional hour to evaluate time
course; again, a transient NE release was seen in the first 20 min
sample ( p 0.007) (Fig. 4D). The mean percentage increase was
similar to that seen with ORX-A activation.
A second infusion of ORX-A at the same site was often unsuc-
cessful in eliciting a second increase in NE (6 of 11 tries). Mechanical
infusion effects (vehicle or vehicle plus peptide) were evaluated by
comparison to a later glutamate infusion at the same site. These
comparisons revealed that NE release was triggered by mechanical
stimulation on 2 of 10 occasions (Fig. 4E).
Discussion
This is the first physiological study to examine the modulatory
effects of ORX-A on the neural mechanisms of attention and
memory processes by way of orexinergic activation of LC neu-
rons. ORX-A application to LC neurons initiated robust, but
transient, NE release in the hippocampus and produced a large
and long-lasting, -adrenergic receptor-dependent potentiation
of the dentate gyrus population spike in anesthetized rat. ORX-A
neurons terminating in the LC provide a pathway for orexinergic
modulation of attention and memory processes in the intact rat
by regulating noradrenergic input to target areas of the LC. The
sensitivity of this system is such that1 fmol of ORX is sufficient
to evoke NE release and facilitate the population spike. The po-
tent effects on the perforant path-evoked potential suggest the
ORX–LC pathway could play a significant role in the neural
plasticity that underlies learning and memory and provides a
mechanism for hypothalamic modulation of cognition. These
results may have clinical relevance, as in narcolepsy, in which
there is an ORX deficit, memory impairments (Henry et al.,
1993), and difficulties with vigilance and attention tasks (Rogers
and Rosenberg, 1990; Rieger et al., 2003).
The long-lasting facilitation of perforant path throughput to
the rest of the trisynaptic hippocampal circuit resulting from
ORX-A infusion into the LC resembles that observed after the
infusion of glutamate infusion into the LC. Both are dependent
on activation of -adrenergic receptors (Harley and Milway,
1986; Harley and Evans, 1988). However, details of the facilita-
tion vary; ORX-A infusion into the LC produces a substantial
(155% of baseline), and consistently enduring, NE-LTP in con-
trast to the more variable effects seen with glutamate infusion.
The overall pattern of potentiation also varies somewhat with an
earlier and more abrupt potentiation after glutamate infusion
and a more gradual increase over time after ORX-A infusion.
Differences between the effects of ORX-A and glutamate on
the firing pattern of LC neurons may explain the variability of
their action on the perforant path population spike. The infusion
of glutamate into the LC results in a 500 msec burst of spikes
recorded from LC neurons, followed by a silent period and then a
gradual return to baseline firing (Harley and Sara, 1992). In con-
trast, ORX-A infusion results in a tonic activation of LC neurons
(Kiyashchenko et al., 2001), through a slower G-protein-coupled
receptor mechanism. When 200 nM ORX-A is infused in the vi-
cinity of the LC, muscle tone modulation parallels, with a delayed
onset, the transient, dose-dependent rise in LC firing (Kiyash-
chenko et al., 2001). Doses in the present study were lower than
those evaluated for changes in muscle tone. It is likely in the
present study that LC neurons were activated tonically, but tran-
siently, by the infusion of ORX-A. ORX also increases synchro-
nous firing of LC neurons (van den Pol et al., 2002). A combina-
tion of tonic firing with enhanced synchrony may be relevant to
the robust, consistent NE-LTP induced by ORX infusion in the
LC. Aston-Jones et al. (1999) have also proposed a unique role for
synchronous LC activity in focused attention.
A new study in our laboratory has shown that glutamatergic
activation of the LC in awake rats produces a delayed -adre-
nergic receptor-dependent facilitation of both the EPSP slope
and population spike amplitude 24 hr after the LC glutamate
infusion, an effect that does not require short-term facilitation
(Walling and Harley, 2004). Whether orexinergic activation of
LC neurons can initiate a similar pattern of synaptic strength
changes at 24 hr remains to be examined.
In the study by Walling and Harley (2004) with intracerebro-
Figure 3. Previous infusion of the2-receptor agonist CLON in the LC prevents potentiation
induced by ORX-A infusion in the LC. Population spike amplitude for rats receiving either 1 nM
ORX-A (n  6) or CLON, followed by 1 nM ORX-A (n  5). CLON prevented the long-term
population spike potentiation observed previously in animals receiving 1 nM ORX-A. The data
are shown as 3 min means SEM. C, CLON.
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ventricular administration of PROP, and in previous in vitro and
in vivo studies with bath-applied (Stanton and Sarvey, 1985b;
Dahl and Sarvey, 1989; Chaulk and Harley, 1998) or systemically
administered (Harley and Milway, 1989) PROP, NE- or LC-
mediated potentiation in the dentate gyrus has been completely
blocked. Local diffusion of a -adrenergic receptor antagonist
from a micropipette, however, attenuates, rather than completely
blocks, NE effects (Munro et al., 2001). Micropipette drug diffu-
sion in the dentate gyrus has been estimated at500 m (Stew-
ard et al., 1990). Some contribution is likely made to the field
potential from sites that are less effectively antagonized account-
ing for the attenuation profile. Nonetheless, the micropipette ap-
proach addresses two issues more effectively than other methods:
it controls for any changes attributable to preparation variability
and it provides evidence that-adrenergic receptors solely within
the dentate gyrus participate in the LC-induced potentiation.
The low doses of ORX-A used in the present study, relative to
previous in vitro and in vivo studies, may account for the lack of
evidence for a dose–response relationship. In a previous in vivo
study (Kiyashchenko et al., 2001), LC infusion of 200 nM pro-
duced longer latency and shorter-duration effects than infusion
of 1 mM ORX-A (a 5000-fold difference in concentration); in the
present study, 100 nM was the highest dose used, and the differ-
ence between the lowest and highest effective doses examined was
100-fold. These low doses, while illustrating the high degree of LC
sensitivity to ORX-A, may also have made site variability more of
an issue for dose–response differences. The 100 pM dose was
ineffective, but, if anything, responses were more robust with 1
nM infusions than with higher concentrations. Consistent with
the lack of a dose–response in the electrophysiological experi-
ments was the lack of a dose–response in the microdialysis stud-
ies. All of the effective ORX-A doses promoted NE release to a
similar extent. The ineffectiveness of repeated doses at the same
site corroborates observations of ORX-A desensitization in vitro
(van den Pol et al., 2002).
Results from the microdialysis experiments demonstrate that
both glutamate and ORX-A activation of LC neurons produce a
transient, but robust, increase in the level of NE in the hippocam-
pus. The long-lasting increase in the pop-
ulation spike (	3 hr) in the face of only a
transient increase in evoked NE release
supports the hypothesis that elevated NE is
an initiating event for the enhancement of
spike amplitude and that elevated NE is
not required for maintenance of that en-
hancement. The greater effectiveness of
ORX-A, relative to glutamate, in promot-
ing consistently enduring NE-LTP may re-
late to the duration or pattern of LC cell
firing induced by ORX-A.
ORX-A appears to recruit and rein-
force forebrain noradrenergic activation
in several ways. In addition to the ability of
ORX-A to directly initiate NE release by
activating the LC, ORX-A promotes NE
release presynaptically when applied to ce-
rebrocortical slices (Hirota et al., 2001).
Other studies have shown intravenous in-
fusions of ORX-A also increase glutamate
release in the LC, suggesting indirect as
well as direct excitatory actions of ORX-A
on LC neurons (Kodama and Kimura,
2002). Thus, multiple mechanisms are in
place to reinforce the ability of ORX-A to modulate behavior
through increases in forebrain NE.
In summary, the present data confirm, in vivo, that ORX-A is
a robust activator of LC neurons and can initiate NE release in an
LC target structure. This ORX-A action promotes an enduring
potentiation in the response of dentate gyrus neurons to their
perforant path-mediated input. Electrophysiological and behav-
ioral studies in awake rats are needed to elaborate this initial
characterization of the effects of ORX-A on attention and mem-
ory mechanisms and on the modulation of NE release.
References
Aldavert-Vera L, Segura-Torres P, Costa-Miserachs D, Morgado-Bernal I
(1996) Shuttle-box memory facilitation by posttraining intracranial self-
stimulation: differential effects in rats with high and low basic condition-
ing levels. Behav Neurosci 110:346 –352.
Aston-Jones G, Shipley MT, Grzanna R (1995) The locus coeruleus, A5 and
A7 noradrenergic cell groups. In: The rat nervous system (Paxinos G, ed),
pp 183–213. San Diego: Academic.
Aston-Jones G, Rajkowski J, Cohen J (1999) Role of locus coeruleus in at-
tention and behavioral flexibility. Biol Psychiatry 46:1309 –1320.
Berridge CW, Waterhouse BD (2003) The locus coeruleus-noradrenergic
system: modulation of behavioral state and state-dependent cognitive
processes. Brain Res Rev 42:33– 84.
Berridge CW, Page ME, Valentino RJ, Foote SL (1993) Effects of locus co-
eruleus inactivation on electroencephalographic activity in neocortex and
hippocampus. Neuroscience 55:381–393.
Bourgin P, Huitron-Resendiz S, Spier AD, Fabre V, Morte B, Criado JR,
Sutcliffe JG, Henriksen SJ, de Lecea L (2000) Hypocretin-1 modulates
rapid eye movement sleep through activation of locus coeruleus neurons.
J Neurosci 20:7760 –7765.
Bramham CR, Bacher-Svendsen K, Sarvey JM (1997) LTP in the lateral per-
forant path is -adrenergic receptor-dependent. NeuroReport 8:719–724.
Chaulk PC, Harley CW (1998) Intracerebroventricular norepinephrine po-
tentiation of the perforant path-evoked potential in dentate gyrus of anes-
thetized and awake rats: a role for both- and-adrenoceptor activation.
Brain Res 787:59 –70.
Coulombe D, White N (1980) The effect of post-training lateral hypotha-
lamic self-stimulation on aversive and appetitive classical conditioning.
Physiol Behav 25:267–272.
Coulombe D, White N (1982) The effect of post-training hypothalamic self-
stimulation on sensory preconditioning in rats. Can J Psychol 36:57– 66.
Figure 4. ORX-A infusion in the LC enhances hippocampal NE release in the first 20 min sample. Microdialysate concentrations
of NE in the hippocampus before (samples3.0 to1.0) and after (samples 1.0 –3.0) infusions into the LC. Baseline levels were
taken as the mean of the three samples taken before LC infusion. Samples of NE diasylate were taken every 20 min. The first sample
after infusion of the three concentrations of ORX-A ( A–C) or after glutamate ( D) was significantly elevated (* is minutes of p
0.05). Vehicle and repeated ORX-A infusions were typically ineffective ( E). In E, the numbers shown on the bars represent the
number of rats sampled.
Walling et al. • Orexin Triggers Noradrenergic LTP in Dentate Gyrus J. Neurosci., August 25, 2004 • 24(34):7421–7426 • 7425
Cutler DJ, Morris R, Sheridhar V, Wattam TAK, Holmes S, Patel S, Arch JRS,
Wilson S, Buckingham RE, Evans ML, Leslie RA, Williams G (1999)
Differential distribution of orexin-A and orexin-B immunoreactivity in
the rat brain and spinal cord. Peptides 20:1455–1470.
Dahl D, Sarvey JM (1989) Norepinephrine induces pathway-specific long-
lasting potentiation and depression in the hippocampal dentate gyrus.
Proc Natl Acad Sci USA 86:4776 – 4780.
Date Y, Ueta Y, Yamashita H, Yamaguchi H, Matsukura S, Kangawa K, Saku-
rai T, Yanagisawa M, Nakazato M (1999) Orexins, orexigenic hypotha-
lamic peptides, interact with autonomic, neuroendocrine and neuroregu-
latory systems. Proc Natl Acad Sci USA 96:748 –753.
de Lecea L, Kilduff TS, Peyron C, Gao XB, Foye PE, Danielson PE, Fukuhara
C, Battenberg ELF, Gautvik VT, Bartlett FS, Frankel WN, van den Pol AN,
Bloom FE, Gautvik KM, Sutcliffe JG (1998) The hypocretins:
hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl
Acad Sci USA 95:322–327.
Destrade C, Jaffard R (1978) Post-trial hippocampal and lateral hypotha-
lamic electrical stimulation. Facilitation on long-term memory of appet-
itive and avoidance learning tasks. Behav Biol 22:354 –374.
Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD,
Taylor SG, Routledge C, Hemmati P, Munton RP, Ashmeade TE, Shah
AS, Hatcher JP, Hatcher PD, Jones DNC, Smith MI, Piper DC, Hunter AJ,
Porter RA, Upton N (1999) Orexin A activates locus coeruleus cell firing
and increases arousal in the rat. Proc Natl Acad Sci USA 96:10911–10916.
Harley CW, Evans S (1988) Locus coeruleus-induced enhancement of the
perforant path-evoked potential: effects of intradentate -blockers. In:
Cellular mechanisms of conditioning and behavioral plasticity (Woody
CD, Alkon DL, McGaugh JL, eds), pp 415– 423. New York: Plenum.
Harley CW, Milway JS (1986) Glutamate ejection in the locus coeruleus
enhances the perforant path-evoked population spike in the dentate gy-
rus. Exp Brain Res 63:143–150.
Harley CW, Sara SJ (1992) Locus coeruleus bursts induced by glutamate
trigger delayed perforant path spike amplitude potentiation in the dentate
gyrus. Exp Brain Res 89:581–587.
Harley CW, Lalies MD, Nutt DJ (1996) Estimating the synaptic concentra-
tion of norepinephrine in dentate gyrus which produces -receptor me-
diated long-lasting potentiation in vivo using microdialysis and intrace-
rebroventricular norepinephrine. Brain Res 710:293–298.
Henry GK, Satz P, Heilbronner RL (1993) Evidence of a perceptual-
encoding deficit in narcolepsy? Sleep 16:123–127.
Hervieu GJ, Cluderay JE, Harrison DC, Roberts JC, Leslie RA (2001) Gene
expression and protein distribution of the orexin-1 receptor in the rat
brain and spinal cord. Neuroscience 103:777–797.
Hirota K, Kushikata T, Kudo M, Kudo T, Lambert DG, Matsuki A (2001)
Orexin A and B evoke noradrenaline release from rat cerebrocortical
slices. Br J Pharmacol 134:1461–1466.
Horvath TL, Peyron C, Diano S, Ivanov A, Aston-Jones G, Kilduff TS, van den
Pol AN (1999) Hypocretin (orexin) activation and synaptic innervation
of the locus coeruleus noradrenergic system. J Comp Neurol
415:145–159.
Huston JP, Mueller CC (1978) Enhanced passive avoidance learning and
appetitive T-maze learning with post-trial rewarding hypothalamic stim-
ulation. Brain Res Bull 3:265–270.
Ivanov A, Aston-Jones G (2000) Hypocretin/orexin depolarizes and de-
creases potassium conductance in locus coeruleus neurons. NeuroReport
11:1755–1758.
Jaeger LB, Farr SA, Banks WA, Morley JE (2002) Effects of orexin-A on
memory processing. Peptides 23:1683–1688.
Kiyashchenko LI, Mileykovskiy BY, Lai YY, Siegel JM (2001) Increased and
decreased muscle tone with orexin (hypocretin) microinjections in the
locus coeruleus and pontine inhibitory area. J Neurophysiol
85:2008 –2016.
Kodama T, Kimura M (2002) Arousal effects of orexin-A correlate with
GLU release from the locus coeruleus in rats. Peptides 23:1673–1681.
Lacaille JC, Harley CW (1985) The action of norepinephrine in the dentate
gyrus: -mediated facilitation of evoked potentials in vitro. Brain Res
358:210 –220.
Loy R, Koziell DA, Lindsey JD, Moore RY (1980) Noradrenergic innerva-
tion of the adult rat hippocampal formation. J Comp Neurol
189:699 –710.
Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M,
Elmquist JK (2001) Differential expression of orexin receptors 1 and 2 in
the rat brain. J Comp Neurol 435:6 –25.
Milner PM (1991) Brain-stimulation reward: a review. Can J Psychol
45:1–36.
Munro CA, Walling SG, Evans JH, Harley CW (2001) -Adrenergic block-
ade in the dentate gyrus in vivo prevents high frequency-induced long-
term potentiation of EPSP slope, but not long-term potentiation of pop-
ulation spike amplitude. Hippocampus 11:322–328.
Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K (1999)
Distribution of orexin neurons in the adult rat brain. Brain Res
827:243–260.
Neuman RS, Harley CW (1983) Long-lasting potentiation of the dentate
gyrus population spike by norepinephrine. Brain Res 273:162–165.
Redolar-Ripoll D, Aldavert-Vera L, Soriano-Mas C, Segura-Torres P,
Morgado-Bernal I (2002) Intracranial self-stimulation facilitates mem-
ory consolidation, but not retrieval: its effects are more effective than
increased training. Behav Brain Res 129:65–75.
Rieger M, Mayer G, Gauggel S (2003) Attention deficits in patients with
narcolepsy. Sleep 26:36 – 43.
Rogers AE, Rosenberg RS (1990) Tests of memory in narcoleptics. Sleep
13:42–52.
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Wil-
liams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JRS, Buckingham
RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA,
Elshourbagy NA, Bergsma DJ, Yanagisawa M (1998) Orexins and orexin
receptors: a family of hypothalamic neuropeptides and G protein-
coupled receptors that regulate feeding behavior. Cell 92:573–585.
Stanton PK, Sarvey JM (1985a) The effect of high-frequency electrical stim-
ulation and norepinephrine on cyclic AMP levels in normal versus
norepinephrine-depleted rat hippocampal slices. Brain Res 358:343–348.
Stanton PK, Sarvey JM (1985b) Blockade of norepinephrine-induced long-
lasting potentiation in the hippocampal dentate gyrus by an inhibitor of
protein synthesis. Brain Res 361:276 –283.
Steward O, Tomasulo R, Levy WB (1990) Blockade of inhibition in a path-
way with dual excitatory and inhibitory action unmasks a capability for
LTP that is otherwise not expressed. Brain Res 516:292–300.
Telegdy G, Adamik A (2002) The action of orexin A on passive avoidance
learning. Involvement of transmitters. Regul Pept 104:105–110.
Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LHT, Guan XM (1998) Distri-
bution of orexin receptor mRNA in the rat brain. FEBS Lett 438:71–75.
van den Pol AN, Ghosh PK, Liu RJ, Li Y, Aghajanian GK, Gao XB (2002)
Hypocretin (orexin) enhances neuron activity and cell synchrony in de-
veloping mouse GFP-expressing locus coeruleus. J Physiol (Lond)
541:169 –185.
Walling SG, Harley CW (2004) Locus ceruleus activation initiates delayed
synaptic potentiation of perforant path input to the dentate gyrus in
awake rats: a novel-adrenergic- and protein synthesis-dependent mam-
malian plasticity mechanism. J Neurosci 24:598 – 604.
7426 • J. Neurosci., August 25, 2004 • 24(34):7421–7426 Walling et al. • Orexin Triggers Noradrenergic LTP in Dentate Gyrus
